Physician profile
Thalia Lopez
NPI 1972197846
$3,688.93
in general payments reported to CMS, 2019-2025
23 companies · $656 in 2025
The $656 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $831 · 2023: $720 · 2024: $845 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,515.13 | 2022-2025 | Sapien 3 Ultra Resilia, Pascal |
| Impulse Dynamics (USA) INC. | $274.57 | 2022-2024 | Optimizer |
| Cvrx, INC. | $265.77 | 2021-2022 | |
| Shockwave Medical, INC | $260.78 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $167.65 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| United Therapeutics Corporation | $147.20 | 2021 | |
| Novo Nordisk INC | $144.06 | 2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $123.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.65 | 2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $81.77 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.74 | 2021-2022 | |
| Medtronic, INC. | $73.04 | 2021-2024 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $62.95 | 2023-2024 | |
| Boston Scientific Corporation | $58.14 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.07 | 2021-2022 | |
| Daiichi Sankyo INC. | $27.23 | 2021-2022 | |
| Altathera Pharmaceuticals LLC | $23.67 | 2022 | |
| Cardiva Medical, INC. | $18.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.41 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.99 | 2021 | |
| Pfizer INC. | $14.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thalia Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.